文献速递妇科

CRLX101单药及联合贝伐珠单抗治疗复发性卵巢癌的序贯II期临床试验

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-07-07

该序贯II期开放标签单臂试验评估了CRLX101单药(n=29)及联合贝伐珠单抗(n=34)治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌的疗效与安全性。单药组临床获益率68%、客观缓解率11%、无进展生存期4.5个月;联合组临床获益率95%、客观缓解率18%、无进展生存期6.5个月。CRLX101耐受性良好,联合贝伐珠单抗安全可行。

要点

  • CRLX101单药治疗复发性卵巢癌临床获益率68%,客观缓解率11%
  • 联合贝伐珠单抗后临床获益率升至95%,客观缓解率18%
  • 联合方案安全可行,主要增加高血压和膀胱毒性但无严重不良事件

核心结论

  • CRLX101满足了对有效且可耐受的拓扑异构酶I抑制剂的需求,并可安全联合贝伐珠单抗。

研究设计与样本

  • 序贯II期开放标签单臂临床试验,评估CRLX101单药(n=29)及联合贝伐珠单抗(n=34)治疗复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌。
  • 单药组允许最多3线既往化疗但排除既往拓扑异构酶I抑制剂,联合组仅纳入铂耐药且既往最多2线治疗的患者。

主要发现

  • 单药组(n=29)中位治疗3个周期(范围1-16),临床获益率68%,客观缓解率11%,无进展生存期4.5个月(范围0.9-15.9个月)。
  • 联合组(n=34)临床获益率95%,客观缓解率18%,无进展生存期6.5个月(范围2.8-14.4个月)。
  • CRLX101耐受性良好,除恶心、疲劳和贫血外;贝伐珠单抗增加高血压发生率并定性增加膀胱毒性,但无严重不良事件。

关键数值与推荐

  • 单药组CRLX101剂量为15 mg/m2静脉注射,每14天一次,28天为一周期,每2周期评估疗效。
  • 联合组贝伐珠单抗剂量为10 mg/kg,第1、15天给药,28天为一周期。

临床怎么用

  • 对于复发性上皮性卵巢癌患者,CRLX101单药或联合贝伐珠单抗可作为耐受性良好的治疗选择。
  • 联合贝伐珠单抗时需监测高血压和膀胱毒性,但无需因严重不良事件而特别担忧。

局限性

  • 研究为单臂设计,缺乏随机对照,样本量较小(单药组29例,联合组34例)。
  • 联合组仅纳入铂耐药且既往治疗线数有限的患者,可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topoisomerase-1 inhibitors are an important class of cytotoxics associated with toxicity that limits their use. CRLX101 is a novel cyclodextrin-containing polymer conjugate of camptothecin (CPT) that self-assembles into nanoparticles to deliver sustained levels of active CPT into cancer cells while substantially reducing systemic exposure. METHODS: We conducted sequential phase II, open label, single arm clinical trials to evaluate CRLX101 as a single agent (n = 29) and with bevacizumab (Bev) (n = 34). Patients (pts) had measurable recurrent epithelial ovarian, tubal or primary peritoneal cancer, that could be platinum refractory, resistant or sensitive. Cohort A (Single agent CRLX101) allowed up to 3 prior chemotherapy regimens, but no prior topo-1 inhibitors. Pts received CRLX101 15 mg/m2 IV every 14 days Q28 with response evaluation every 2 cycles. Cohort B also received Bev 10 mg/kg D1,15 Q28, and included only platinum resistant disease with up to 2 prior lines, and more rigorous eligibility criteria. RESULTS: CRLX101 was well tolerated other than nausea, fatigue and anemia. 29 pts. received a median of 3 (1-16) cycles with a clinical benefit rate (CBR) of 68% and overall response rate (ORR) of 11%. With the addition of Bev in Cohort B (n = 34), the CBR was increased to 95% and the ORR to 18%. PFS was 4.5 months (0.9 to 15.9 months) in Cohort A and 6.5 months (2.8 to 14.4 months) in Cohort B. Bev increased the incidence of hypertension and qualitatively increased bladder toxicities, but without SAEs. CONCLUSIONS: CRLX101 meets the clinical need for an effective and tolerable topoisomerase I inhibitor and can be safely combined with bevacizumab.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Krasner CN, Campos SM, Young CL, et al. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021. PMID: 34243976. doi:10.1016/j.ygyno.2021.07.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。